![Jonathan Finn](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jonathan Finn
Direktor/Vorstandsmitglied bei
ATOSSA THERAPEUTICS, INC.
Vermögen: 25 315 $ am 31.10.2026
Profil
Mr. Jonathan F.
Finn, CFA, is an Independent Director at Atossa Therapeutics, Inc., a General Partner at Scientia Ventures LLC, a Chief Investment Officer at Vantage Consulting Group, Inc., a Director at eReceivables Inc. and Solör Bioenergi Holding AB. He is on the Board of Directors at Atossa Therapeutics, Inc. and Verigraft AB. He is an investment professional over a 25 years’ experience at the firm.
Mr. Finn also served on the board at Rose Pharma A/S and Solør Bioenergi Holding AS.
He received his BA in Economics from the University of Virginia.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.05.2026 | 11 666 ( 0,12 % ) | 25 315 $ | 31.10.2026 |
Aktive Positionen von Jonathan Finn
| Unternehmen | Position | Beginn |
|---|---|---|
| ATOSSA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 08.11.2023 |
Vantage Consulting Group, Inc.
 Vantage Consulting Group, Inc. Investment ManagersFinance Vantage strives to deliver a comprehensive, bespoke investment solution firmly grounded in fundamental investment principles. At the core of this solution lies an investment strategy meticulously tailored to their clients’ unique investment objectives, risk tolerances, diversification preferences, and their specific liquidity needs and investment horizons. | Chief Investment Officer | 01.06.1995 |
Scientia Ventures LLC
 Scientia Ventures LLC Investment ManagersFinance Scientia Ventures invests in companies located in the United States. The firm focuses on companies operating in the fields of computational biology and chemistry, the digitization of medicine, and digital therapies as well as traditional drug development companies at the cutting edge of the life sciences. It participates in early stage transactions. | Chief Investment Officer | 01.01.2006 |
Verigraft
 Verigraft BiotechnologyHealth Technology Engages in development of personalized human tissues for transplantation | Direktor/Vorstandsmitglied | - |
Solör Bioenergi Holding AB
 Solör Bioenergi Holding AB Electric UtilitiesUtilities Produces and distributes district heating, steam & electricity | Private Equity Investor | - |
ERECEIVABLES INC.
 ERECEIVABLES INC. Information Technology ServicesTechnology Services Provides information technology services that simplified the handling of insurance claims appeals | Private Equity Investor | - |
Ehemalige bekannte Positionen von Jonathan Finn
| Unternehmen | Position | Ende |
|---|---|---|
Rose Pharma A/S
 Rose Pharma A/S Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products for treatment of pain in connection with irritable bowel syndrome | Private Equity Investor | - |
Solør Bioenergi Holding AS
 Solør Bioenergi Holding AS Electric UtilitiesUtilities Produces, distributes and sells wood-based bioenergy | Private Equity Investor | - |
Ausbildung von Jonathan Finn
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
42
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Atossa Therapeutics, Inc.
 Atossa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics and delivery methods for the treatment of breast cancer & other breast conditions | Health Technology |
University of Virginia
 University of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rose Pharma A/S
Rose Pharma A/S Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products for treatment of pain in connection with irritable bowel syndrome | Health Technology |
Vantage Consulting Group, Inc.
Vantage Consulting Group, Inc. Investment ManagersFinance Vantage strives to deliver a comprehensive, bespoke investment solution firmly grounded in fundamental investment principles. At the core of this solution lies an investment strategy meticulously tailored to their clients’ unique investment objectives, risk tolerances, diversification preferences, and their specific liquidity needs and investment horizons. | Finance |
Solør Bioenergi Holding AS
Solør Bioenergi Holding AS Electric UtilitiesUtilities Produces, distributes and sells wood-based bioenergy | Utilities |
Solör Bioenergi Holding AB
Solör Bioenergi Holding AB Electric UtilitiesUtilities Produces and distributes district heating, steam & electricity | Utilities |
Scientia Ventures LLC
Scientia Ventures LLC Investment ManagersFinance Scientia Ventures invests in companies located in the United States. The firm focuses on companies operating in the fields of computational biology and chemistry, the digitization of medicine, and digital therapies as well as traditional drug development companies at the cutting edge of the life sciences. It participates in early stage transactions. | Finance |
Verigraft
Verigraft BiotechnologyHealth Technology Engages in development of personalized human tissues for transplantation | Health Technology |
ERECEIVABLES INC.
ERECEIVABLES INC. Information Technology ServicesTechnology Services Provides information technology services that simplified the handling of insurance claims appeals | Technology Services |
